Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
Returns on capital
Connect Biopharma Holdings Limited management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-132.2%
avg 66.6%
ROIC
-135.7%
avg -85.6%
ROA
-98.9%
avg -135.8%
Analysis
ROA is currently the strongest return metric at -98.9% versus its period average of -135.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Barry D. Quart | Chief Executive Officer & Director | USD 980.22K | 69 | 0 | <0.01% |
David L. Szekeres | President | USD 734.97K | 52 | — | — |
Lisa Peraza | Senior Vice President of Finance | USD 571.13K | 49 | 0 | <0.01% |
Jeff Cohn | General Counsel & Corporate Secretary | — | 44 | — | — |
Lei Sun | Vice President of Biologics & Head of CMC | — | 62 | — | — |
Sean T. Ristine | Vice President of Human Resources | — | 56 | — | — |
Srikanth Pendyala | Senior Vice President of Clinical Development(Consultant) | — | — | — | — |
Kimberly J. Manhard | Executive Vice President & Chief Development Officer | — | 66 | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$4.37M
Sells
0
$0.00
Net Transaction Value
+$4.37M
Net buying
Most Active
Huang James
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 29, 26May 29, 2026 | Huang James Indirect | Buy | $371.6K$371,610.00 |
| Mar 31, 26Mar 31, 2026 | Huang James Indirect | Buy | $4M$4,002,000.00 |
Summary
Insiders reported 2 buys worth $4.37M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $4.37M. Huang James was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +300.6% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +300.6% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Connect Biopharma Holdings Limited compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CNTB's management, answered from reported figures.
Who manages CNTB?
Connect Biopharma Holdings Limited (CNTB) lists 8 active executives. The top listed executive is Barry D. Quart, Chief Executive Officer & Director.
Are CNTB insiders buying or selling?
Recent insider activity shows net buying of $4.37M.
Continue the stock analysis
Jump to another research area for this company.